title: [About the impact of the dendritic cell autovaccine on the results of treatment of non-small-cell lung cancer patients].
abstract: In thoracic department of the National Cancer Institute studied the effectiveness of dendritic cell autovaccine in the postoperative period in non-small-cell lung cancer patients. The results, showing good tolerance dendritic cell autovaccine. Shows the formation of the expressed antigen immune response after repeated injections dendritic cell autovaccine, as manifested after 4 revaccination. Results of survival patients non-small-cell lung cancer who received postoperative dendritic cell autovaccines demonstrate the high efficiency of the method and its applicability with a minimum of side effects. Further study of survival of patients non-small-cell lung cancer who received immunotherapy treatment, monitoring of compliance with the best mode of repeated injections.
authors.forename: V M
authors.initials: VM
authors.lastname: Sovenko
authors.forename: N N
authors.initials: NN
authors.lastname: Khranovskaia
authors.forename: A V
authors.initials: AV
authors.lastname: Ganul
authors.forename: V L
authors.initials: VL
authors.lastname: Ganul
authors.forename: Iu A
authors.initials: IuA
authors.lastname: Grinevich
authors.forename: V É
authors.initials: VÉ
authors.lastname: Orel
authors.forename: O V
authors.initials: OV
authors.lastname: Skachkova
authors.forename: N N
authors.initials: NN
authors.lastname: Svergun
authors.forename: L V
authors.initials: LV
authors.lastname: Bororov
authors.forename: B O
authors.initials: BO
authors.lastname: Borisiuk
authors.forename: O I
authors.initials: OI
authors.lastname: Kobzev
authors.forename: A I
authors.initials: AI
authors.lastname: Shevchenko
authors.forename: A V
authors.initials: AV
authors.lastname: Semivolos
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Kondratskiĭ
mesh_terms: D000368:Aged; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D060846:Cell Engineering; D002478:Cells, Cultured; D017024:Chemotherapy, Adjuvant; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines